Human serum induces apoptosis of xenogenic cardiomyocytes in vivo and in vitro.
Discordant xenotransplantation is complicated by delayed xenograft rejection (DXR). Previous studies have demonstrated that anti-apoptotic genes are protective against DXR. This study examines the hypothesis that apoptosis plays a role in human anti-xenograft responses. C57BL/6 mice and NOD SCID mice were given a single intravenous injection of either a lethal dose (LD, survival < 30 min) or a sublethal dose (SLD) of human serum, and isolated pig and mouse rod-shaped cardiomyocytes were exposed to human serum in vitro. In situ detection of apoptotic cells in mouse hearts was assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nicked-end labeling assay. Mice transfused with human serum had approximately a 10-fold increased percentage of apoptotic cells after SLD 18 h post-injection compared with animals given saline, and a fourfold increase over LD. Administration of cobra venom factor (CVF) decomplemented SLD 18 h did not significantly (P > 0.05) alter the percentage apoptosis. The addition of 20 mM Gal-alpha-1,3-Gal to SLD 18 h significantly (P < 0.05) reduced percentage apoptosis to levels comparable to saline treated control animals. In vitro using mouse and pig cardiomyocytes demonstrated parallel results as in vivo experiments. Human serum induces apoptosis of cardiomyocytes in immunocompetent and immunoincompetent mice in vivo, as well as mouse and pig cardiomyocytes in vitro. Further, this apoptotic response can be inhibited by the addition of Gal-alpha-1,3-Gal without affecting the capacity of the serum to cause HAR. These results demonstrate that a putative human serum factor induces a delayed apoptotic injury of xenograft tissues, and supports the hypothesis that apoptosis may be an important mediator of DXR.
Lucien
J
J
The Hospital for Sick Children, Toronto, Canada.
Shimada
M
M
Watzka
S
S
Ogiwara
M
M
Brockhausen
I
I
Sandhu
J
J
Coles
J G
JG
D000818:Animals; D015478:Antigens, Heterophile / Q000008:administration & dosage* / Q000276:immunology*; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology*; D001666:Binding Sites, Antibody; D001769:Blood / Q000276:immunology*; D002478:Cells, Cultured; D003165:Complement System Proteins / Q000502:physiology; D004187:Disaccharides / Q000276:immunology / Q000494:pharmacology; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000276:immunology / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009130:Muscle, Smooth / Q000166:cytology* / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D009206:Myocardium / Q000166:cytology* / Q000276:immunology* / Q000473:pathology; D009336:Necrosis; D013552:Swine; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism
D015478:Antigens, Heterophile; D004187:Disaccharides; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C055075:galactosyl-(1-3)galactose; D003165:Complement System Proteins